Zofran Zydis 8mg
- Name:
Zofran Zydis 8mg
- Company:
Novartis Ireland Limited
- Active Ingredients:
- Legal Category:
Product subject to medical prescription which may not be renewed (A)
Patient Information Leaflet Patient Information Leaflet last updated on medicines.ie: 10/09/19
(Click to Download)Click on this link to Download PDF directly
Novartis Ireland Limited
Company Products
When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.
Updated on 10 September 2019 PIL
Reasons for updating
- Change to section 2 - pregnancy, breast feeding and fertility
Updated on 12 April 2019 SmPC
Reasons for updating
- Change to section 4.6 - Pregnancy and lactation
- Change to section 4.7 - Effects on ability to drive and use machines
- Change to section 5.3 - Preclinical safety data
- Change to section 10 - Date of revision of the text
Legal category: Product subject to medical prescription which may not be renewed (A)
Updated on 23 January 2019 PIL
Reasons for updating
- Change to section 6 - marketing authorisation holder
- Change to section 6 - manufacturer
- Change to section 6 - date of revision
Updated on 19 July 2018 SmPC
Reasons for updating
- Change to section 7 - Marketing authorisation holder
- Change to section 8 - Marketing authorisation number(s)
Legal category: Product subject to medical prescription which may not be renewed (A)
Updated on 15 November 2016 PIL
Reasons for updating
- New PIL for new product
Updated on 15 November 2016 PIL
Reasons for updating
- Change to section 3 - overdose, missed or forgotten doses
- Change to section 6 - date of revision
Updated on 25 August 2016 SmPC
Reasons for updating
- New SmPC for new product
Legal category: Product subject to medical prescription which may not be renewed (A)
Updated on 25 August 2016 SmPC
Reasons for updating
- Change to section 4.9 - Overdose
- Change to section 10 - Date of revision of the text
Legal category: Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
Updated on 10 February 2016 SmPC
Reasons for updating
- Change to marketing authorisation holder
Legal category: Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
Updated on 1 February 2016 SmPC
Reasons for updating
- Change to section 4.1 - Therapeutic indications
- Change to section 4.2 - Posology and method of administration
- Change to section 4.8 - Undesirable effects
- Change to section 10 - Date of revision of the text
Legal category: Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
Section 4.2. Addition of ‘IV’ to Table 2 for consistency with Table 1.
Section 4.8. Update to include toxic skin eruption, including toxic epidermal necrolyis as an Undesirable Effect.
Section 4.8 Update to provide clarification on the setting of dizziness, and existing Undesirable Effect.
Updated on 28 January 2016 PIL
Reasons for updating
- Change to side-effects
- Change to date of revision
- Change to MA holder contact details
Updated on 10 December 2015 SmPC
Reasons for updating
- Change to section 4.9 - Overdose
- Change to section 10 - Date of revision of the text
Legal category: Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
Updated on 21 July 2015 SmPC
Reasons for updating
- Change to section 10 - Date of revision of the text
- Change to MA holder contact details
Legal category: Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
Updated on 20 July 2015 PIL
Reasons for updating
- Change to date of revision
- Change to MA holder contact details
Updated on 13 April 2015 SmPC
Reasons for updating
- Change to section 4.2 - Posology and method of administration
- Change to Section 4.8 – Undesirable effects - how to report a side effect
- Change to section 10 - Date of revision of the text
- Correction of spelling/typing errors
Legal category: Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
4.2 addition of dosing regime (spoonful)
4.8 addition of how to report an adverse event
Updated on 10 April 2015 PIL
Reasons for updating
- Change to date of revision
- Addition of information on reporting a side effect.
Updated on 24 February 2014 SmPC
Reasons for updating
- Change to section 4.2 - Posology and method of administration
- Change to section 4.3 - Contraindications
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
- Change to section 4.9 - Overdose
- Change to section 5.1 - Pharmacodynamic properties
- Change to section 5.2 - Pharmacokinetic properties
- Change to section 5.3 - Preclinical safety data
Legal category: Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
Section 4.2 - Posology and method of administration,
Section 4.3 - Contraindications,
Section 4.4 - Special warnings and precautions for use,
Section 4.5 - Interaction with other medicinal products and other forms of interaction,
Section 4.9 - Overdose,
Section 5.1 - Pharmacodynamic properties,
Section 5.2 - Pharmacokinetic properties,
Section 5.3 - Preclinical safety data
Updated on 19 February 2014 PIL
Reasons for updating
- Change to drug interactions
- Change to dosage and administration
Updated on 25 July 2012 PIL
Reasons for updating
- Change to warnings or special precautions for use
- Change of contraindications
- Change to side-effects
- Change to drug interactions
Updated on 1 June 2012 SmPC
Reasons for updating
- Change to section 4.3 - Contraindications
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
- Change to section 4.8 - Undesirable effects
Legal category: Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
Change to:
Section 4.3 - Contraindications,
Section 4.4 - Special warnings and precautions for use,
Section 4.5 - Interaction with other medicinal products and other forms of interaction,
Section 4.8 - Undesirable effects
Updated on 23 August 2011 SmPC
Reasons for updating
- Change to section 2 - Qualitative and quantitative composition
- Change to section 4.2 - Posology and method of administration
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.7 - Effects on ability to drive and use machines
- Change to section 4.8 - Undesirable effects
- Change to section 5.1 - Pharmacodynamic properties
- Change to section 5.2 - Pharmacokinetic properties
- Change to section 5.3 - Preclinical safety data
- Change to section 6.6 - Special precautions for disposal and other handling
Legal category: Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
Changes to the following:
· Section 2
· Section 4.2
· Section 4.4
· Section 4.7
· Section 4.8
· Section 5.1
· Section 5.2
· Section 5.3
· Section 6.6
Updated on 4 January 2011 PIL
Reasons for updating
- Change to storage instructions
Updated on 22 September 2010 SmPC
Reasons for updating
- Change to section 1 - Name of medicinal product
- Change to section 2 - Qualitative and quantitative composition
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
- Change to section 6.1 - List of excipients
- Change to section 6.2 - Incompatibilities
- Change to section 6.4 - Special precautions for storage
- Change to section 6.5 - Nature and contents of container
- Change to section 6.6 - Special precautions for disposal and other handling
- Change to section 9 - Date of renewal of authorisation
- Change to section 10 - Date of revision of the text
Legal category: Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
1. TRADE NAME OF THE MEDICINAL PRODUCT
Zofran Zydis 4 mg Oral Lyophilisate 4mg
************************************************
2. QUALITATIVE AND QUANTITATIVE COMPOSITION
Each Zofran Zydis oral lyophilisate contains ondansetron 4 mg.
Each 4 mg Oral Lyophilisate contains 625 micrograms of aspartame (E951), 56 micrograms sodium methyl parahydroxybenzoate (E219) and 6.9 micrograms of sodium propyl parahydroxybenzoate (E217).
For a full list of excipients, see Ssection 6.1.
************************************************
4.5 Interaction with Other Medicaments Medicinal products and Other Forms of Interaction
There is no evidence that ondansetron either induces or inhibits the metabolism of other drugs commonly co-administered with it. Specific studies have shown that there are no pharmacokinetic interactions when ondansetron is administered with alcohol, temazepam, frusemide, tramadol and propofol.
Ondansetron is metabolised by multiple hepatic cytochrome P450 enzymes: CYP3A4, CYP2D6 and CYP1A2. Due to the multiplicity of metabolic enzymes capable of metabolising ondansetron, enzyme inhibition or reduced activity of one enzyme (e.g. CYP2D6 genetic deficiency) is normally compensated by other enzymes and should result in little or no significant change in overall ondansetron clearance or dose requirement.
Phenytoin, Carbamazepine and Rifampicin
In patients treated with potent inducers of CYP3A4 (i.e. phenytoin, carbamazepine and rifampicin), the oral clearance of ondansetron was increased and ondansetron blood concentrations were decreased.
Tramadol
Data from small studies indicate that ondansetron may reduce the analgesic effect of tramadol.
************************************************
6. PHARMACEUTICAL PARTICULARS
6.1 List of Excipients
Gelatin
Mannitol (E421)
Aspartame (E951)
Sodium methyl parahydroxybenzoate (E219)
Sodium propyl parahydroxybenzoate (E217)
Strawberry flavour
************************************************
6.2 Incompatibilities
None reported.Not applicable.
************************************************
6.4 Special Precautions for Storage
Do not store above 30°C.
Store in the original package in order to protect from light and moisture.
************************************************
6.5 Nature and Contents of Container
Double foil blister packs, consisting of a PVC/Polyamide/Aluminium/Polyamide an aluminium foil laminate base with a peelable, aluminium foil laminate lidding, inside a paperboard carton.
Each pack contains 10 Zofran Zydis oral lyophilisate dosage units.
************************************************
6.6 Instructions for Use/HandlingSpecial precautions for disposal of a used medicinal product or waste materials derived from such medicinal product and other handling of the product
DO NOT attempt to push Zofran Zydis through the lidding foil.
PEEL BACK the lidding foil of one blister and GENTLY remove the Zofran Zydis.
Place the Zofran Zydis on top of the tongue, where it will disperse within seconds, then swallow.
Any unused product should be disposed of in accordance with local requirements.
************************************************
9. DATE OF FIRST AUTHORISATION/RENEWAL OF AUTHORISATION
13th July 1998 / 13th July 20083
************************************************
10. DATE OF (PARTIAL) REVISION OF THE TEXT
February 2007August 2010
Updated on 29 August 2007 PIL
Reasons for updating
- Improved electronic presentation
Updated on 27 August 2007 SmPC
Reasons for updating
- Improved electronic presentation
Legal category: Product subject to medical prescription which may not be renewed (A)
Updated on 16 April 2007 PIL
Reasons for updating
- Change to side-effects
Updated on 17 October 2005 PIL
Reasons for updating
- Improved electronic presentation
Updated on 22 July 2005 SmPC
Reasons for updating
- Change to section 4.8 - Undesirable effects
Legal category: Product subject to medical prescription which may not be renewed (A)
Updated on 13 October 2004 PIL
Reasons for updating
- New PIL for medicines.ie
Updated on 6 October 2004 SmPC
Reasons for updating
- New SPC for new product
Legal category: Product subject to medical prescription which may not be renewed (A)